Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual M...
October 10 2017 - 10:00AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report
on the Symposium on Fexapotide Triflutate studies to be held at the
Annual Meeting of the American Urological Association Northeastern
Section, in Savannah GA this week. The symposium, “Fexapotide
Triflutate: A Safe and Effective First In Class Injectable for BPH”
will be chaired by James Bailen MD FACS of Louisville, KY. The
other panel members at the Symposium will be Dr. Franklin D. Gaylis
of San Diego CA, Dr. Stephen Richardson of Salt Lake City UT, and
Dr. Jed Kaminetsky of New York NY.
The Symposium will present detailed clinical
data on the Phase 3 clinical trials that have been completed for
Fexapotide and that have shown excellent safety and significant
efficacy for the treatment of BPH. In addition, scientific data
supporting the safety and efficacy from non-clinical and laboratory
testing and analysis will be demonstrated. The main presentation
will be followed by a panel discussion and by an interactive
question and answer session with the specialist doctors in
attendance.
Nymox's lead drug Fexapotide has been in
development for over 10 years and has been tested by expert
clinical trial investigative teams in over 70 distinguished
clinical trial centers throughout the US, and has been found after
7 years of prospective placebo controlled double blind studies of
treatment of 995 U.S. men with prostate enlargement to not only
show clinically meaningful and durable relief of BPH symptoms, but
also to show a major reduction in the incidence of prostate cancer,
compared to placebo and compared to the known and expected normal
incidence of the disease. The same clinical program has also shown
in a long-term blinded placebo crossover group study an 82-95%
reduction in the number of these patients who required surgery
after they received crossover Fexapotide in the trial, as compared
to patients who did not receive Fexapotide but instead received
crossover conventional approved BPH treatments (p<.0001).
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2016, and its Quarterly Reports.
For Further Information Contact:Paul
AverbackNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024